


AMENDMENTS TO THE CLAIMS


1. (previously presented): A compound of the formula



or a pharmaceutically acceptable salt thereof; wherein

Ar represents an optionally substituted 2-, 3- or 4-pyridyl, indolyl, 2- or 4-pyrimidyl, pyridazinyl, benzotriazol or benzimidazolyl,

with a proviso that optionally substituted Ar is not



wherein R⁵ is H, alkyl (1-6C), alkenyl (2-6C), alkynyl (2-6C), an aromatic or heteroaromatic moiety containing 5-11 ring members;

X is NR¹, or S;

R¹ is H, alkyl (1-8C), alkenyl (2-8C), or alkynyl (2-8C);

Z represents CR⁴;

each of R³ and R⁴ is independently H, alkyl, alkenyl, alkynyl, acyl, aryl, alkylaryl, aroyl, O-aryl, O-alkylaryl, O-aroyl, NR-aryl, NR-alkylaryl, NR-aroyl, or the hetero forms of any of the foregoing, halo, OR, NR₂, SR, -SOR, -NRSOR, -NRSO₂R, -SO₂R, -OCOR, -NRCOR, -NRCONR₂, -NRCOOR, -OCONR₂, -COOR, -SO₃R, -CONR₂, -SO₂NR₂, -CN, -CF₃, or -NO₂, wherein each R is independently H or alkyl (1-10C);

wherein any alkyl, alkenyl, alkynyl, acyl or aryl groups contained in R³ and/or R⁴ may contain one or more heteroatoms and/or optionally be further substituted;

each R² is independently-alkyl, alkenyl, alkynyl, acyl, aryl, alkylaryl, aroyl, O-aryl, O-alkylaryl, O-aroyl, NR-aryl, NR-alkylaryl, NR-aroyl, or the hetero forms of any of the foregoing, halo, OR, NR₂, SR, -SOR, -NRSOR, -NRSO₂R, -SO₂R, -OCOR, -NRCOR, -NRCONR₂, -NRCOOR, -OCONR₂, -COOR, -SO₃R, -CONR₂, -SO₂NR₂, -CN, -CF₃, or -NO₂, wherein each R is independently H or lower alkyl (1-4C), wherein any alkyl, alkenyl, alkynyl, acyl or aryl groups contained in R² may contain one or more heteroatoms and/or may optionally be further substituted; and

n is 0-5.

2. (canceled)

3. (canceled)

4. (original): The compound of claim 1, wherein the substituents on the aromatic moiety of Ar are selected from the group consisting of alkyl, alkenyl, alkynyl, acyl, aryl, alkylaryl, aroyl, O-aryl, O-alkylaryl, O-aroyl, NR-aryl, NR-alkylaryl, NR-aroyl, or the hetero forms of any of the foregoing, halo, OR, NR₂, SR, -SOR, -NRSOR, -NRSO₂R, -SO₂R, -OCOR, -NRCOR, -NRCONR₂, -NRCOOR, -OCONR₂, -COOR, -SO₃R, -CONR₂, -SO₂NR₂, -CN, -CF₃, and -NO₂, wherein each R is independently H or alkyl (1-10C), and wherein any alkyl, alkenyl, alkynyl, acyl or aryl moieties contained in the substituent may contain one or more heteroatoms and/or may further be substituted by the foregoing substituents.

5. (previously presented): The compound of claim 1, wherein Ar is optionally substituted indolyl, benzimidazolyl, pyridazinyl, benzotriazol or 2-pyridyl.

6. (original): The compound of claim 1, wherein n is 0-3.

7. (original): The compound of claim 1, wherein R¹ is H or lower alkyl (1-4C).

8. (previously presented): The compound of claim 1, wherein each R^3 and R^4 is independently H, alkyl (1-10C), OR, SR or NR_2 wherein R is H or alkyl (1-10C), each optionally substituted.
9. (original): The compound of claim 8, wherein said optional substituent is an aromatic moiety or a heterocyclic moiety, each optionally substituted.
10. (original): The compound of claim 9, wherein at least one of R^3 and R^4 is H.
11. (previously presented): The compound of claim 1, wherein each R^2 is independently alkyl, alkoxy, or halo.
12. (original): The compound of claim 11, wherein each R^2 is independently halo.
13. (original): The compound of claim 4, wherein the substituents on the aromatic moiety of Ar are selected from the group consisting of alkyl, O-aryl, O-alkylaryl, NR-aryl, and N-alkylaryl wherein any alkyl or aryl contained in said substituent may further optionally be substituted.
14. (previously presented): The compound of claim 13, wherein said aromatic moiety of Ar includes 0, 1 or 2 substituents.
15. (previously presented): The compound of claim 14, wherein said aromatic moiety of Ar includes 0 or 1 substituents.
16. (previously presented): The compound of claim 1, wherein each R^3 and R^4 is independently H, CN, COOR, OR, SR, NR_2 , alkyl (1-6C), acyl (1-6C), aryl, aryloxy, arylalkyloxy, wherein R is H or alkyl (1-10C) and wherein any alkyl or aryl portions of said substituents may further be substituted with the foregoing.

17. (previously presented): The compound of claim 1, wherein X is NH.
18. (previously presented): The compound of claim 1, wherein Ar is optionally substituted 3-pyridyl, 4-pyrimidyl, or 2-pyrimidyl.
19. (previously presented): The compound of claim 1, wherein Ar is optionally substituted 4-pyridyl.
20. (currently amended): A method to treat ~~conditions~~ a fibroproliferative disorder or cancer associated with unwanted activity of TGF β ,

which method comprises administering to a subject in need of such treatment an effective amount of the compound of claim 1 or a pharmaceutical composition thereof.
21. (previously presented): A pharmaceutical composition which comprises the compound of claim 1 in admixture with at least one pharmaceutically acceptable excipient.
22. (previously presented) The compound of claim 17, wherein n is 1 or 2.
23. (currently amended) The method of claim 20, wherein the condition ~~associated with unwanted activity of TGF- β is a fibroproliferative disease, an autoimmune disorder, or a condition associated with eye surgery~~ is fibrosis of the liver.